Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.
Adolescent
Adult
Aged
Combined Modality Therapy
Disease Management
Female
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Induction Chemotherapy
Leukemia, Myeloid, Acute
/ diagnosis
Male
Middle Aged
Nucleophosmin
Prognosis
Retrospective Studies
Transplantation, Autologous
Treatment Outcome
Young Adult
Acute myeloid leukemia (AML)
NPM1 mutation
autologous SCT (ASCT)
core-binding factor (CBF) translocation
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
4
4
2019
medline:
18
8
2020
entrez:
4
4
2019
Statut:
ppublish
Résumé
Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk AML patients. Sixty-six patients were included: 32 had mutated NPM1/wild-type FLT-ITD, 16 had t(8:21) and 18 - inv(16). Forty patients received chemotherapy alone, 26 underwent ASCT upfront. In time-dependent analysis, the ASCT group demonstrated higher relapse-free (RFS) (
Identifiants
pubmed: 30943060
doi: 10.1080/10428194.2019.1594214
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2449-2456Commentaires et corrections
Type : CommentIn